ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP announced an investigation into Alnylam Pharmaceuticals regarding potential violations of securities laws. The firm claims the investigation focuses on whether the company issued misleading statements, following a 28.4% stock drop after Alnylam lowered its TTR product sales guidance.
Key figures
- Stock drop percentage
- 28.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.